DHA Supplementation in Patients With STGD3

Clinical Interventions Against Stargardt Macular Dystrophy: DHA Supplementation in Patients With STGD3

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00420602

Enrollment

Registered

2007-01-11

Start date

2007-09-21

Completion date

2017-12-27

Last updated

2018-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dominantly Inherited Stargardt's Disease (STGD3)

Brief summary

We have found that biomarkers of long-term elevated dietary intake of omega-3 fatty acids such as DHA and EPA are inversely associated with severity of disease phenotype in STGD3 patients. Therefore, the purpose of this study is to follow STGD3 patients as they supplement their diets with DHA/EPA.

Interventions

DIETARY_SUPPLEMENTOver the counter DHA/EPA dietary supplementation

1000 mg/day DHA/EPA

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 105 Years

Healthy volunteers

Inclusion criteria

* All Moran Eye Center patients with STGD3

Exclusion criteria

* All others

Design outcomes

Primary

Measure	Time frame
ERG	1 year

Secondary

Measure	Time frame
Visual acuity	1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026